126 related articles for article (PubMed ID: 38795461)
41. High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma.
Sun L; Sakurai S; Sano T; Hironaka M; Kawashima O; Nakajima T
Pathol Int; 2009 Aug; 59(8):522-9. PubMed ID: 19627535
[TBL] [Abstract][Full Text] [Related]
42. TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection.
Miyagawa-Hayashino A; Okada S; Takeda-Miyata N; Takashima Y; Yamada T; Takemura Y; Uchino J; Inoue M; Takayama K; Konishi E
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):313-320. PubMed ID: 33031101
[TBL] [Abstract][Full Text] [Related]
43. [Clinical Analysis of 22 Cases of Pulmonary Large Cell Neuroendocrine Cancer].
Qian Z; Hu Y; Zheng H; Dong Y; Wang Q; Li B
Zhongguo Fei Ai Za Zhi; 2016 Feb; 19(2):82-7. PubMed ID: 26903161
[TBL] [Abstract][Full Text] [Related]
44. Pulmonary large cell carcinoma with neuroendocrine morphology shows genetic similarity to large cell neuroendocrine carcinoma.
Liang Z; Wang W; Hu Q; Zhou P; Zhang Y; Tang Y; Wu Q; Fu Y; Li X; Shao Y; Jiang L
Diagn Pathol; 2022 Feb; 17(1):26. PubMed ID: 35144629
[TBL] [Abstract][Full Text] [Related]
45. Pathologic diagnosis of large cell neuroendocrine carcinoma of the lung in an axillary lymph node: a case report with immunohistochemical and molecular genetic studies.
Terada T
Int J Clin Exp Pathol; 2013; 6(6):1177-9. PubMed ID: 23696939
[TBL] [Abstract][Full Text] [Related]
46. Large cell neuroendocrine carcinoma of the larynx: definition of an entity.
Lewis JS; Spence DC; Chiosea S; Barnes EL; Brandwein-Gensler M; El-Mofty SK
Head Neck Pathol; 2010 Sep; 4(3):198-207. PubMed ID: 20589486
[TBL] [Abstract][Full Text] [Related]
47. Pulmonary Large Cell Neuroendocrine Carcinoma.
Yang L; Fan Y; Lu H
Pathol Oncol Res; 2022; 28():1610730. PubMed ID: 36304941
[TBL] [Abstract][Full Text] [Related]
48. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
Rossi G; Cavazza A; Marchioni A; Longo L; Migaldi M; Sartori G; Bigiani N; Schirosi L; Casali C; Morandi U; Facciolongo N; Maiorana A; Bavieri M; Fabbri LM; Brambilla E
J Clin Oncol; 2005 Dec; 23(34):8774-85. PubMed ID: 16314638
[TBL] [Abstract][Full Text] [Related]
49. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma.
Hiroshima K; Iyoda A; Shibuya K; Haga Y; Toyozaki T; Iizasa T; Nakayama T; Fujisawa T; Ohwada H
Cancer; 2004 Mar; 100(6):1190-8. PubMed ID: 15022286
[TBL] [Abstract][Full Text] [Related]
50. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.
Milione M; Maisonneuve P; Grillo F; Mangogna A; Centonze G; Prinzi N; Pusceddu S; Garzone G; Cattaneo L; Busico A; Bossi P; Spaggiari P; Pellegrinelli A; Del Gobbo A; Ferrero S; Kankava K; Pruneri G; Rolli L; Roca E; Bercich L; Tironi A; Benvenuti MR; Gallazzi MS; Romano R; Berruti A; Pastorino U; Capella C
Neuroendocrinology; 2021; 111(5):475-489. PubMed ID: 32365350
[TBL] [Abstract][Full Text] [Related]
51. Reproducibility of neuroendocrine lung tumor classification.
Travis WD; Gal AA; Colby TV; Klimstra DS; Falk R; Koss MN
Hum Pathol; 1998 Mar; 29(3):272-9. PubMed ID: 9496831
[TBL] [Abstract][Full Text] [Related]
52. Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies.
Yokota E; Iwai M; Yukawa T; Naomoto Y; Haisa M; Monobe Y; Takigawa N; Fukazawa T; Yamatsuji T
Cancer Lett; 2024 Apr; 588():216816. PubMed ID: 38499265
[TBL] [Abstract][Full Text] [Related]
53. Urinary Large Cell Neuroendocrine Carcinoma: A Clinicopathologic Analysis of 22 Cases.
Wang G; Yuan R; Zhou C; Guo C; Villamil C; Hayes M; Eigl BJ; Black P
Am J Surg Pathol; 2021 Oct; 45(10):1399-1408. PubMed ID: 34074810
[TBL] [Abstract][Full Text] [Related]
54. Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma.
Makino T; Mikami T; Hata Y; Otsuka H; Koezuka S; Isobe K; Tochigi N; Shibuya K; Homma S; Iyoda A
Ann Thorac Surg; 2016 Nov; 102(5):1694-1701. PubMed ID: 27368130
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.
Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795
[TBL] [Abstract][Full Text] [Related]
56. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
[TBL] [Abstract][Full Text] [Related]
57. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
58. Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.
Bean GR; Najjar S; Shin SJ; Hosfield EM; Caswell-Jin JL; Urisman A; Jones KD; Chen YY; Krings G
Mod Pathol; 2022 Oct; 35(10):1349-1361. PubMed ID: 35590107
[TBL] [Abstract][Full Text] [Related]
59. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
[TBL] [Abstract][Full Text] [Related]
60. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.
Walter RF; Mairinger FD; Werner R; Vollbrecht C; Hager T; Schmid KW; Wohlschlaeger J; Christoph DC
Oncotarget; 2016 Apr; 7(15):20166-79. PubMed ID: 27064343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
